FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969857570> ?p ?o ?g. }

• W1969857570 endingPage "188" @default.
• W1969857570 startingPage "188" @default.
• W1969857570 abstract "<h3>Background</h3> Adalimumab, an anti TNF-α agent, has been proven to be safe and effective in treatment of ankylosing spondylitis (AS). A biosimilar adalimumab was approved for use by Indian regulators in 2014. It is a “fingerprint match” of the reference adalimumab in terms of purity, potency, safety and clinical efficacy.^1,2 ln the absence of availability of adalimumab in India, this biosimilar adalimumab currently serves as an accessible, cost-effective option for treatment of AS patients. <h3>Objectives</h3> This retrospective analysis evaluates effectiveness of biosimilar adalimumab (bADA), in terms of disease activity, safety and outcomes in real-life Indian AS patients treated for initial 24 weeks and then followed for next 24 weeks off biologic treatment. <h3>Methods</h3> Medical records of AS patients with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) >4, who were prescribed bADA therapy between January to December 2015 were analysed. For patients, who stopped bADA treatment after 24 weeks, standard AS outcome-measurement scores including ESR, CRP, BASDAI, BASFI, and Health Assessment Questionnaire (HAQ) at baseline, week 24 and at week 48 were measured to evaluate ongoing efficacy, were compared using paired Student9s T-test. Patients were allowed to continue methotrexate and salazopyrin as part of routine medical care. <h3>Results</h3> During the study period, 52 AS patients were prescribed bADA 40 mg s/c; 24 of these patients, who had stopped treatment after 6 months, were considered for this analysis. Mean age for this group was 36.57±10.81 years; 10 females. At the end of 24 weeks9 treatment, there were significant reductions in levels of inflammatory markers ESR, CRP, as well as in BASDAI, BASFI and HAQ scores. Eight patients continued to receive methotrexate and 8 patients sulfasalazine as concomitant medications. After week 48 (24 weeks post stoppage), BASDAI and BASFI scores did not deteriorate despite discontinuation of bADA treatment. The patients9 HAQ scores were also indicative of similar trends of continuing improved health status post the therapy. <h3>Conclusions</h3> Biosimilar adalimumab therapy was effective in treating AS patients. The disease activity and health assessment scores continued to remain stable with no worsening after the stoppage of treatment for 6 months, indicating a post-therapy effectiveness in these patients with no reported adverse event. <h3>References</h3> Bandyopadhyay S, et al. Biosimilars. 2015;5:1–18. Jani RH et al. int J Rheum Dis. 2015 Jul 14. <h3>Disclosure of Interest</h3> None declared" @default.
• W1969857570 created "2016-06-24" @default.
• W1969857570 creator A5045241947 @default.
• W1969857570 date "1980-01-19" @default.
• W1969857570 modified "2023-09-26" @default.
• W1969857570 title "Grades, status, and titles" @default.
• W1969857570 doi "https://doi.org/10.1136/bmj.280.6208.188-b" @default.
• W1969857570 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1600311" @default.
• W1969857570 hasPublicationYear "1980" @default.
• W1969857570 type Work @default.
• W1969857570 sameAs 1969857570 @default.
• W1969857570 citedByCount "1" @default.
• W1969857570 countsByYear W19698575702018 @default.
• W1969857570 crossrefType "journal-article" @default.
• W1969857570 hasAuthorship W1969857570A5045241947 @default.
• W1969857570 hasConcept C126322002 @default.
• W1969857570 hasConcept C1862650 @default.
• W1969857570 hasConcept C2776260265 @default.
• W1969857570 hasConcept C2777138892 @default.
• W1969857570 hasConcept C2777226972 @default.
• W1969857570 hasConcept C2777402515 @default.
• W1969857570 hasConcept C2777453003 @default.
• W1969857570 hasConcept C2777575956 @default.
• W1969857570 hasConcept C2779134260 @default.
• W1969857570 hasConcept C2779650986 @default.
• W1969857570 hasConcept C2780132546 @default.
• W1969857570 hasConcept C2780415856 @default.
• W1969857570 hasConcept C59491497 @default.
• W1969857570 hasConcept C71924100 @default.
• W1969857570 hasConceptScore W1969857570C126322002 @default.
• W1969857570 hasConceptScore W1969857570C1862650 @default.
• W1969857570 hasConceptScore W1969857570C2776260265 @default.
• W1969857570 hasConceptScore W1969857570C2777138892 @default.
• W1969857570 hasConceptScore W1969857570C2777226972 @default.
• W1969857570 hasConceptScore W1969857570C2777402515 @default.
• W1969857570 hasConceptScore W1969857570C2777453003 @default.
• W1969857570 hasConceptScore W1969857570C2777575956 @default.
• W1969857570 hasConceptScore W1969857570C2779134260 @default.
• W1969857570 hasConceptScore W1969857570C2779650986 @default.
• W1969857570 hasConceptScore W1969857570C2780132546 @default.
• W1969857570 hasConceptScore W1969857570C2780415856 @default.
• W1969857570 hasConceptScore W1969857570C59491497 @default.
• W1969857570 hasConceptScore W1969857570C71924100 @default.
• W1969857570 hasIssue "6208" @default.
• W1969857570 hasLocation W19698575701 @default.
• W1969857570 hasOpenAccess W1969857570 @default.
• W1969857570 hasPrimaryLocation W19698575701 @default.
• W1969857570 hasRelatedWork W1969857570 @default.
• W1969857570 hasRelatedWork W2052900499 @default.
• W1969857570 hasRelatedWork W2102994864 @default.
• W1969857570 hasRelatedWork W2124093381 @default.
• W1969857570 hasRelatedWork W2135717214 @default.
• W1969857570 hasRelatedWork W2148305943 @default.
• W1969857570 hasRelatedWork W2167191466 @default.
• W1969857570 hasRelatedWork W2323888127 @default.
• W1969857570 hasRelatedWork W2331167095 @default.
• W1969857570 hasRelatedWork W2754678896 @default.
• W1969857570 hasVolume "280" @default.
• W1969857570 isParatext "false" @default.
• W1969857570 isRetracted "false" @default.
• W1969857570 magId "1969857570" @default.
• W1969857570 workType "article" @default.